AU2023202089B2 — Pemetrexed formulations
Assigned to Eagle Pharmaceuticals Inc · Expires 2025-05-29 · 1y expired
What this patent protects
The present invention relates to ready to use, intravenous liquid pharmaceutical compositions comprising pemetrexed, a non-aqueous solvent consisting of propylene glycol, tromethamine, and water which remain stable undiluted for 24 months and after dilution for at least 12 hour…
USPTO Abstract
The present invention relates to ready to use, intravenous liquid pharmaceutical compositions comprising pemetrexed, a non-aqueous solvent consisting of propylene glycol, tromethamine, and water which remain stable undiluted for 24 months and after dilution for at least 12 hours when stored at 2C to 8C. The present invention also relates to methods of treating pleural mesothelioma or non-squamous, non-small cell lung cancer comprising administration of said compositions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.